Formulated for osteoporosis and breast cancer risk reduction to manage bone density and support long-term wellness.
Mechanism of Action
Raloxifene is a selective estrogen receptor modulator. It acts as an estrogen agonist in bone, maintaining mineral density, and as an antagonist in breast and uterine tissues, reducing the risk of hormone-sensitive cancers.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
28 hours (half-life)
Contraindications
History of thromboembolic disorders, Pregnancy, Hypersensitivity to raloxifene
Severe Adverse Events
Deep vein thrombosis, Pulmonary embolism, Stroke — requires immediate medical attention
Common Side Effects
Hot flashes, Leg cramps, Sweating
Uncommon Side Effects
Peripheral edema, Flu-like symptoms, Arthralgia
Drug Interactions
Alcohol, Warfarin, Cholestyramine, Levothyroxine
Pregnancy Safety Warnings
FDA Category X: Strictly contraindicated in pregnancy. Breastfeeding: Not applicable.
Information related to Raloxifene is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
